{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:18:05Z","timestamp":1772482685932,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T00:00:00Z","timestamp":1515628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10147-018-1241-3","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T09:30:55Z","timestamp":1515663055000},"page":"559-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-656X","authenticated-orcid":false,"given":"Hiroki","family":"Ishihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Omae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohito","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,11]]},"reference":[{"key":"1241_CR1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.juro.2012.04.108","volume":"188","author":"R Figlin","year":"2012","unstructured":"Figlin R, Sternberg C, Wood CG (2012) Novel agents and approaches for advanced renal cell carcinoma. J Urol 188:707\u2013715","journal-title":"J Urol"},{"key":"1241_CR2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124","journal-title":"N Engl J Med"},{"key":"1241_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11523-016-0463-4","volume":"12","author":"I Duran","year":"2017","unstructured":"Duran I, Lambea J, Maroto P et al (2017) Resistance to targeted therapies in renal cancer: the importance of changing the mechanism of action. Target Oncol 12:19\u201335","journal-title":"Target Oncol"},{"key":"1241_CR4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ejca.2012.02.048","volume":"48","author":"C Seidel","year":"2012","unstructured":"Seidel C, Busch J, Weikert S et al (2012) Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Eur J Cancer (Oxford, England: 1990) 48:1023\u20131030","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"1241_CR5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2016.05.049","volume":"71","author":"JC Wells","year":"2017","unstructured":"Wells JC, Stukalin I, Norton C et al (2017) Third-line targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 71:204\u2013209","journal-title":"Eur Urol"},{"key":"1241_CR6","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/bjc.2014.25","volume":"110","author":"JJ Ko","year":"2014","unstructured":"Ko JJ, Choueiri TK, Rini BI et al (2014) First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer 110:1917\u20131922","journal-title":"Br J Cancer"},{"key":"1241_CR7","doi-asserted-by":"crossref","unstructured":"Oudard S, Geoffrois L, Guillot A et al (2016) Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma\u2014results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) study. Eur J Cancer (Oxford, England: 1990) 62:28\u201335","DOI":"10.1016\/j.ejca.2016.04.003"},{"key":"1241_CR8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.urolonc.2013.12.007","volume":"32","author":"T Buchler","year":"2014","unstructured":"Buchler T, Bortlicek Z, Poprach A et al (2014) Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis. Urol Oncol 32:569\u2013575","journal-title":"Urol Oncol"},{"key":"1241_CR9","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00280-015-2725-8","volume":"75","author":"I Park","year":"2015","unstructured":"Park I, Lee JL, Ahn JH et al (2015) Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor. Cancer Chemother Pharmacol 75:1025\u20131035","journal-title":"Cancer Chemother Pharmacol"},{"key":"1241_CR10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2012.09.004","volume":"64","author":"J Busch","year":"2013","unstructured":"Busch J, Seidel C, Erber B et al (2013) Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma. Eur Urol 64:62\u201370","journal-title":"Eur Urol"},{"key":"1241_CR11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00345-016-1868-5","volume":"35","author":"J Bedke","year":"2017","unstructured":"Bedke J, Gauler T, Grunwald V et al (2017) Systemic therapy in metastatic renal cell carcinoma. World J Urol 35:179\u2013188","journal-title":"World J Urol"},{"key":"1241_CR12","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1038\/bjc.2014.244","volume":"110","author":"B Escudier","year":"2014","unstructured":"Escudier B, Michaelson MD, Motzer RJ et al (2014) Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 110:2821\u20132828","journal-title":"Br J Cancer"},{"issue":"403\u2013410","key":"1241_CR13","first-page":"e402","volume":"15","author":"G Velasco De","year":"2017","unstructured":"De Velasco G, Xie W, Donskov F et al (2017) Discontinuing VEGF-targeted therapy for progression versus toxicity affects outcomes of second-line therapies in metastatic renal cell carcinoma. Clin Genitourin Cancer 15(403\u2013410):e402","journal-title":"Clin Genitourin Cancer"},{"key":"1241_CR14","doi-asserted-by":"crossref","unstructured":"Ishihara H, Kondo T, Yoshida K et al (2017) Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy. Urol Oncol 35(9):542.e1\u2013542.e9","DOI":"10.1016\/j.urolonc.2017.05.014"},{"key":"1241_CR15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10147-016-1032-7","volume":"22","author":"H Ishihara","year":"2017","unstructured":"Ishihara H, Yagisawa T, Kondo T et al (2017) Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. Int J Clin Oncol 22:126\u2013135","journal-title":"Int J Clin Oncol"},{"key":"1241_CR16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","volume":"22","author":"RJ Motzer","year":"2004","unstructured":"Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454\u2013463","journal-title":"J Clin Oncol"},{"key":"1241_CR17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","volume":"71","author":"S Fernandez-Pello","year":"2017","unstructured":"Fernandez-Pello S, Hofmann F, Tahbaz R et al (2017) A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol 71:426\u2013436","journal-title":"Eur Urol"},{"key":"1241_CR18","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/cncr.28151","volume":"119","author":"N Kroeger","year":"2013","unstructured":"Kroeger N, Xie W, Lee JL et al (2013) Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 119:2999\u20133006","journal-title":"Cancer"},{"key":"1241_CR19","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.clgc.2013.12.003","volume":"12","author":"N Alimohamed","year":"2014","unstructured":"Alimohamed N, Lee JL, Srinivas S et al (2014) A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 12:e127\u2013e131","journal-title":"Clin Genitourin Cancer"},{"key":"1241_CR20","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.clgc.2014.08.013","volume":"13","author":"DM Geynisman","year":"2015","unstructured":"Geynisman DM, Hu JC, Liu L et al (2015) Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. Clin Genitourin Cancer 13:e93\u2013e100","journal-title":"Clin Genitourin Cancer"},{"key":"1241_CR21","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1241-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1241-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1241-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T13:03:00Z","timestamp":1526302980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1241-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,11]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1241"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1241-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,11]]}}}